Emerging treatments

OBI-3424

OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent.[171] AKR1C3 is upregulated in certain tumour cell types, but not expressed in normal healthy cells. OBI-3424 has received US Food and Drug Administration (FDA) designation as an orphan drug for the treatment of T-ALL. One phase 2 clinical trial is recruiting.[172]

Inotuzumab ozogamicin plus TKI (for relapsed or refractory Ph+ ALL)

In a phase 1/2 trial, inotuzumab ozogamicin with bosutinib resulted in an objective response rate of 81% in 18 patients (16 patients with relapsed-refractory Ph+ B-ALL and 2 with chronic myeloid leukaemia in lymphoid blast phase).[173]

Use of this content is subject to our disclaimer